FRA3B and other common fragile sites: the weakest links (original) (raw)

• Cohen, A. J. et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301, 592–595 (1979).
  CAS PubMed Google Scholar
• Glover, T. W., Berger, C., Coyle, J. & Echo, B. DNA polymerase-α inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet. 67, 136–142 (1984).Reports that the breaks and gaps induced by aphidicolin represent a new class of fragile sites: the common fragile sites.
  CAS PubMed Google Scholar
• Yunis, J. J. & Soreng, A. L. Constitutive fragile sites and cancer. Science 226, 1199–1204 (1984).Notes that locations of about half of the common fragile sites seem cytogenetically to coincide with locations of specific chromosome translocations that are associated with human cancers and might be near proto-oncogenes.
  CAS PubMed Google Scholar
• Ohta, M. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587–597 (1996).Reports the cloning of the FHIT gene, the t(3;8) translocation, the FRA3B fragile site and homozygous deletions in cancer cells.
  CAS Google Scholar
• Zimonjic, D. B. et al. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res. 57, 1166–1170 (1997).
  CAS PubMed Google Scholar
• Huebner, K., Sozzi, G., Brenner, C., Pierotti, M. A. & Croce, C. M. Fhit loss in lung cancer: diagnostic & therapeutic implications. Adv. Oncol. 15, 3–10 (1999).
  Google Scholar
• Croce, C. M., Sozzi, G. & Huebner, K. Role of FHIT in human cancer. J. Clin. Oncol. 17, 1618–1624 (1999).
  CAS PubMed Google Scholar
• Siprashvili, Z. et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl Acad. Sci. USA 94, 13771–13776 (1997).The first report of suppression of cancer-cell tumorigenicity by overexpression of exogenous Fhit.
  CAS PubMed Google Scholar
• Sard, L. et al. The tumour-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl Acad. Sci. USA 96, 8489–8492 (1999).
  CAS PubMed Google Scholar
• Ji, L. et al. Induction of apoptosis and inhibition of tumorigenicity & tumour growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59, 3333–3339 (1999).The first report of induction of apoptosis in cancer cells that are transfected with an adenovirus that encodes FHIT.
  CAS PubMed Google Scholar
• Richards, R. I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17, 339–345 (2001).
  CAS PubMed Google Scholar
• Glover, T. W. in Genetic Instabilities and Neurological Diseases (eds Wells, R. D & Warren, S. T.) 75–83 (Academic, San Diego, 1998).
  Google Scholar
• Kuwano, A. & Kajii, T. Synergistic effect of aphidicolin and ethanol on the induction of common fragile sites. Hum. Genet. 75, 75–78 (1987).
  CAS PubMed Google Scholar
• Dan, S., Cologne, J. B. & Nefushi, K. Effect of radiation and cigarette smoke on expression of FUdR-inducible common fragile sites in human peripheral lymphocytes. Mutat. Res. 334, 197–203 (1995).
  Google Scholar
• Glover, T. W. & Stein, C. K. Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet. 43, 265–273 (1988).
  CAS PubMed PubMed Central Google Scholar
• Wang, N. D., Testa, J. R. & Smith, D. I. Determination of the specificity of aphidicolin-induced breakage of the human 3p14.2 fragile site. Genomics 17, 341–347 (1993).
  CAS PubMed Google Scholar
• Rassool, F. V. et al. Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites. Proc. Natl Acad. Sci. USA 88, 6657–6661 (1991).
  CAS PubMed Google Scholar
• Coquelle, A., Toledo, F., Stern, S., Bieth, A. & Debatisse, M. A new role for hypoxia in tumour progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs & HSRs. Mol. Cell 2, 259–265 (1998).
  CAS PubMed Google Scholar
• Inoue, H. et al. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc. Natl Acad. Sci. USA 94, 14584–14589 (1997).
  CAS PubMed Google Scholar
• Mimori, K. et al. Cancer specific chromosome alterations in the constitutive fragile region, FRA3B. Proc. Natl Acad. Sci. USA 96, 7456–7461 (1999).
  CAS PubMed Google Scholar
• Mishmar, D. et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc. Natl Acad. Sci. USA 95, 8141–8146 (1998).Reports cloning and characterization of FRA7H.
  CAS PubMed Google Scholar
• Huang, H. et al. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosom. Cancer 24, 48–55 (1999).
  CAS PubMed Google Scholar
• Tatarelli, C., Linnenbach, A., Mimori, K. & Croce, C. M. Characterization of the human testin gene localized in the FRA7G region at 7q31.2. Genomics 68, 1–12 (2000).References 22 and 23 report the cloning and partial characterization of FRA7G.
  CAS PubMed Google Scholar
• Ried, K. et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9, 1651–1663 (2000).
  CAS PubMed Google Scholar
• Arlt, M. F., Miller, D. E., Beer, D. G. & Glover, T. W. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosom. Cancer 33, 82–92 (2002).Identification and sequencing of the FRAXB region, and characterization of deletions in FRAXB in oesophageal cancer cells.
  CAS PubMed Google Scholar
• Glover, T. W. et al. The murine Fhit gene is highly similar to its human ortholog and maps to a common fragile site region. Cancer Res. 58, 3409–3414 (1998).Reports that the mouse orthologue of Fhit also encompasses a fragile site: Fra14A2.
  CAS PubMed Google Scholar
• Shiraishi, T. et al. Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc. Natl Acad. Sci. USA 98, 5722–5727 (2001).The first comparison of orthologous fragile-site sequences of two species, mouse and human.
  CAS PubMed Google Scholar
• Laird, C., Jaffe, E. Karpsen, G., Lamb, M. & Nelson, R. Fragile sites in human chromsomes as regions of late-replicating DNA. Trends Genet. 3, 274–281 (1987).Indicates that fragile sites replicate late in the cell cycle and that, during replication stress, condensation of sequences might not be complete, causing the appearance of a fragile site.
  CAS Google Scholar
• Le Beau, M. M. et al. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum. Mol. Genet. 7, 755–761 (1998).Reports that delay of replication of FRA3B by aphidicolin causes fragile-site expression as gaps and breaks.
  CAS PubMed Google Scholar
• Li, F. P. et al. Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Ann. Intern. Med. 118, 106–111 (1993).
  CAS PubMed Google Scholar
• Croce, C. M. Role of chromosome translocations in neoplasia. Cell 49, 155–156 (1987).
  CAS PubMed Google Scholar
• Rowley, J. D. Chromosome translocations: dangerous liaisons revisited. Nature Rev. Cancer 1, 245–250 (2001).
  CAS Google Scholar
• Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971).
  Google Scholar
• Knudson, A. G., Hethcote, H. W. & Brown, B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl Acad. Sci. USA 72, 5116–5120 (1975).
  PubMed Google Scholar
• Sozzi, G. et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85, 17–26 (1996).
  CAS PubMed Google Scholar
• Werner, N. S. et al. Differentail susceptibility of renal carcinoma cell lines to tumour suppression by exogenous Fhit expression. Cancer Res. 60, 2780–2785 (2000).
  CAS PubMed Google Scholar
• Otterson, G. A. et al. Protein expression and functional analysis of the FHIT gene in human tumour cells. J. Natl Cancer Inst. 90, 426–432 (1998).
  CAS PubMed Google Scholar
• Wu, R., Connolly, D. C., Dunn, R. L. & Cho, K. R. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J. Natl Cancer Inst. 92, 338–344 (2000).Reports lack of suppression of tumorigenicity of some cancer cells after FHIT transfections.
  CAS PubMed Google Scholar
• Ishii, H. et al. Effect of adenoviral transduction of FHIT into esophageal cancer cells. Cancer Res. 61, 1578–1589 (2001).
  CAS PubMed Google Scholar
• Dumon, K. R. et al. FHIT expression delays tumour development and induces apoptosis in human pancreatic cancer. Cancer Res. 61, 4827–4836 (2001).
  CAS PubMed Google Scholar
• Kholodnyuk, I. D., Szeles, A., Yang, Y., Klein, G. & Imreh, S. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumours. Cancer Res. 60, 7119–7125 (2000).
  CAS PubMed Google Scholar
• Barnes, L. D. et al. Fhit, a putative tumour suppressor in humans, is a dinucleoside 5,5′-P1,P3-triphosphate hydrolase. Biochemistry 35, 11529–11535 (1996).
  CAS Google Scholar
• Pace, H. C. et al. Genetic, biochemical and crystallographic definition of a substrate analog complex with the fragile histidine triad protein as the active signalling form of Fhit. Proc. Natl Acad. Sci. USA 95, 5484–5489 (1998).
  CAS PubMed Google Scholar
• Pekarsky, Y. et al. Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 95, 8744–8749 (1998).
  CAS PubMed Google Scholar
• Brenner, C., Bieganowski, P., Pace, H. C. & Huebner, K. The histidine triad superfamily of nucleotide-binding proteins. J. Cell. Physiol. 181, 179–187 (1999).
  CAS PubMed PubMed Central Google Scholar
• Murphy, G. A., Halliday, D. & McLennan, A. G. The Fhit tumour suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. Cancer Res. 60, 2342–2344 (2000).
  CAS PubMed Google Scholar
• Pace, H. C. & Brenner, C. The nitrilase superfamily: classification, structure and functions. Genome Biol. 2, 0001.1–0001.9 (2001).
  Google Scholar
• Chaudhuri, A. R. et al. The tumour suppressor protein Fhit. J. Biol. Chem. 274, 24378–24382 (1999).
  CAS PubMed Google Scholar
• Pekarsky, Y. et al. The murine Fhit locus: isolation, characterization and expression in normal and tumour cells. Cancer Res. 58, 3401–3408 (1998).
  CAS PubMed Google Scholar
• Fong, L. Y. Y. et al. Muir–Torre-like syndrome in Fhit deficient mice. Proc. Natl Acad. Sci. USA 97, 4742–4747 (2000).Reports the development of Fhit knockout mice, their exquisite carcinogen susceptibility and development of a carcinogen-induced Muir–Torre-like syndrome.
  CAS PubMed Google Scholar
• Zanesi, N. et al. The tumour spectrum in Fhit deficient mice. Proc. Natl Acad. Sci. USA 98,10250–10255 (2001).Provides evidence that Fhit might be a one-hit tumour suppressor, at least in some mouse tissues.
  CAS PubMed Google Scholar
• Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. & Kemp, C. J. The murine gene p27 Kip1 is haplo-insufficient for tumour suppression. Nature 396, 177–180 (1998).
  CAS PubMed PubMed Central Google Scholar
• Hilgers, W. et al. Genomic FHIT analysis in RER+ and RER− adenocarcinomas of the pancreas. Genes Chromosom. Cancer 27, 239–243 (2000).
  CAS PubMed Google Scholar
• Mimori, K. et al. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma. Cancer Res. 61, 7379–7382 (2001).
  PubMed Google Scholar
• Hansan, L.-E., Sparen, P. & Nyren, O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int. J. Cancer 54, 402–407 (1993).
  Google Scholar
• Mori, M. et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60, 1177–1182 (2000).
  CAS PubMed Google Scholar
• Michael, D., Beer, D. G., Wilke, C. W., Miller, D. E. & Glover, T. W. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15, 1553–1559 (1997).
  Google Scholar
• Schrump, D. S., Chen, G. A., Consuli, U., Jin, X. & Roth, J. A. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther. 3, 357–364 (1996).
  CAS PubMed Google Scholar
• Dumon, K. R. et al. FHIT gene therapy prevents tumour development in Fhit-deficient mice. Proc. Natl Acad. Sci. USA 98, 3346–3351 (2001).Reports prevention of in vivo carcinogen-induced cancers in mice by infection with Fhit -encoding adenoviruses.
  CAS PubMed Google Scholar
• Hellman, A. et al. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol. Cell Biol. 20, 4420–4427 (2000).
  CAS PubMed PubMed Central Google Scholar
• Hurlstone, A. F. et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18, 1881–1890 (1999).
  CAS PubMed Google Scholar
• Bednarek, A. K. et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res. 60, 2140–2145 (2000).Reports the cloning and preliminary characterization of the WWOX gene.
  CAS PubMed Google Scholar
• Paige, A. J. W. et al. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res. 60, 1690–1697 (2000).Reports homozygous deletions in WWOX in cancer cells.
  CAS PubMed Google Scholar
• Mangelsdorf, M. et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res. 60, 1683–1689 (2000).Reports that WWOX encompasses FRA16D.
  CAS PubMed Google Scholar
• Chang, N.-S. et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumour necrosis factor cytotoxicity. J. Biol. Chem. 276, 3361–3370 (2001).
  CAS PubMed Google Scholar
• Paige, A. J. W. et al. WWOX: a candidate tumour suppressor gene involved in multiple tumour types. Proc. Natl Acad. Sci. USA 98, 11417–11422 (2001).Reports WWOX deletion in primary ovarian carcinoma.
  CAS PubMed Google Scholar
• Bednarek, A. K. et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. (in the press). Reports that WWOX inhibits tumorigenicity of a breast cancer cell line in vivo.
• Krummel, K. A., Roberts, L. R., Kawakami, M., Glover, T. W. & Smith, D. I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69, 37–46 (2000).
  CAS PubMed Google Scholar
• Yakicier, M. C. et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20, 5232–5238 (2001).
  CAS PubMed Google Scholar
• Ingvarsson, S. et al. Reduced Fhit expression in familial and sporadic breast carcinomas. Cancer Res. 59, 2682–2689 (1999).
  CAS PubMed Google Scholar
• Burke, L. et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res. 58, 2533–2536 (1998).
  CAS PubMed Google Scholar
• Tomizawa, Y. et al. Clinicopathological significance of Fhit protein expression in stage 1 non-small cell lung carcinoma. Cancer Res. 58, 5478–5483 (1998).
  CAS PubMed Google Scholar
• Ingvarsson, S., Sigbjornsdottir, B. I., Huiping, C., Jonasson, J. G. & Agnarsson, B. A. Alterations of the FHIT gene in breast cancer: association with tumour progression and patient survival. Cancer Detect. Prev. 25, 318–324 (2001).
  Google Scholar
• Capuzzi, D. et al. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88, 24–34 (1999).
  Google Scholar
• Lee, J. I. et al. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res. 61, 837–841 (2001).
  CAS PubMed Google Scholar
• Krivak, T. C. et al. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res. 61, 4382–4385 (2001).
  CAS PubMed Google Scholar
• Yoshino, K. et al. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int. J. Cancer 85, 6–13 (2000).
  CAS PubMed Google Scholar
• Connolly, D. C. et al. Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin. Cancer Res. 6, 3505–3510 (2000).
  CAS PubMed Google Scholar
• Mao, L. et al. Clonal genetic alterations in the lungs of current and former smokers. J. Natl Cancer Inst. 89, 857–862 (1997).Shows that deletions in 3p at the FHIT locus occur in histologically normal lung cells of smokers.
  CAS PubMed Google Scholar
• Tseng, J. E. et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 59, 4798–4803 (1999).Biopsies of 43% of chronic smokers show decreased Fhit expression.
  CAS PubMed Google Scholar
• Wistuba, I. I. et al. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl Cancer Inst. 89, 1366–1373 (1997).
  CAS PubMed PubMed Central Google Scholar
• Ramesh, R. et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumour suppressor genes using an improved liposome vector. Mol Ther 3, 337–350 (2001).
  CAS PubMed Google Scholar